克拉霉素-萘普生-奥司他韦联合治疗住院甲型H3N2流感患者的疗效:一项开放标签随机对照IIb/III期试验
该研究为开放标签随机对照试验,纳入217例住院甲型H3N2流感成人患者,比较2天克拉霉素-萘普生-奥司他韦联合方案与5天奥司他韦单药的疗效与安全性。
要点
- 联合治疗降低30天和90天死亡率及住院时间。
- 联合治疗减少高依赖病房入住和病毒滴度。
- 联合治疗降低神经氨酸酶抑制剂耐药准种比例。
核心结论
- 联合治疗降低30天和90天死亡率及住院时间。
研究设计与样本
- 前瞻性开放标签随机对照IIb/III期试验,2015年2月至4月开展。
- 成人住院甲型H3N2流感患者随机1:1分配至联合治疗组(克拉霉素500mg、萘普生200mg、奥司他韦75mg每日两次,共2天,随后奥司他韦3天)或对照组(奥司他韦75mg每日两次,共5天,无安慰剂)。
- 共纳入217例患者,联合治疗组107例;中位年龄80岁,53.5%为男性。
主要发现
- 不良事件不常见。
关键数值与推荐
- 联合治疗方案:克拉霉素500mg、萘普生200mg、奥司他韦75mg每日两次,共2天,随后奥司他韦75mg每日两次,共3天。
- 对照组方案:奥司他韦75mg每日两次,共5天,无安慰剂。
- 主要终点:30天死亡率;次要终点包括90天死亡率、鼻咽 aspirate 病毒滴度、神经氨酸酶抑制剂耐药准种比例、肺炎严重指数和住院时间。
临床怎么用
- 对于住院甲型H3N2流感成人患者,可考虑克拉霉素-萘普生-奥司他韦联合治疗以降低死亡率和缩短住院时间。
- 联合治疗可能减少神经氨酸酶抑制剂耐药准种的出现。
局限性
- 开放标签设计,未设安慰剂对照。
- 样本量有限,中位年龄80岁,结果推广需谨慎。
- 需进一步研究该联合方案的抗病毒和免疫调节作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Influenza causes excessive hospitalizations and deaths. The study assessed the efficacy and safety of a clarithromycin-naproxen-oseltamivir combination for treatment of serious influenza. METHODS: From February to April 2015, we conducted a prospective open-label, randomized, controlled trial. Adult patients hospitalized for A(H3N2) influenza were randomly assigned to a 2-day combination of clarithromycin 500 mg, naproxen 200 mg, and oseltamivir 75 mg twice daily, followed by 3 days of oseltamivir or to oseltamivir 75 mg twice daily without placebo for 5 days as a control method (1:1). The primary end point was 30-day mortality. The secondary end points were 90-day mortality, serial nasopharyngeal aspirate (NPA) virus titer, percentage of neuraminidase-inhibitor-resistant A(H3N2) virus (NIRV) quasispecies, pneumonia severity index (PSI), and duration of hospital stay. RESULTS: Among the 217 patients with influenza A(H3N2) enrolled, 107 were randomly assigned to the combination treatment. The median age was 80 years, and 53.5% were men. Adverse events were uncommon. Ten patients died during the 30-day follow-up. The combination treatment was associated with lower 30-day mortality (P = .01), less frequent high dependency unit admission (P = .009), and shorter hospital stay (P < .0001). The virus titer and PSI (days 1-3; P < .01) and the NPA specimens with NIRV quasispecies ≥ 5% (days 1-2; P < .01) were significantly lower in the combination treatment group. Multivariate analysis showed that combination treatment was the only independent factor associated with lower 30-day mortality (OR, 0.06; 95% CI, 0.004-0.94; P = .04). CONCLUSIONS: Combination treatment reduced both 30- and 90-day mortality and length of hospital stay. Further study of the antiviral and immunomodulatory effects of this combination treatment of severe influenza is warranted. TRIAL REGISTRY: BioMed Central; No.: ISRCTN11273879 DOI 10.1186/ISRCTN11273879; URL: www.isrctn.com/ISRCTN11273879.
引用
- Hung IFN, To KKW, Chan JFW, et al. Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial. Chest. 2016. PMID: 27884765. doi:10.1016/j.chest.2016.11.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。